Novartis News | finanzen.ch

Novartis Aktie VALOR 1200526 / ISIN CH0012005267

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

23.06.22	Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments (GlobeNewswire)
23.06.22	Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors (GlobeNewswire)
21.06.22	Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent (GlobeNewswire)
17.06.22	Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA (GlobeNewswire)
16.06.22	New research reveals the critical actions needed to ensure COVID-19-driven surge in virtual health and care drives health access and equity (GlobeNewswire)
12.06.22	Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL (GlobeNewswire)
12.06.22	Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL (GlobeNewswire)
07.06.22	Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial (GlobeNewswire)
06.06.22	Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study (GlobeNewswire)
31.05.22	Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030 (GlobeNewswire)
28.05.22	FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma (GlobeNewswire)
27.05.22	Sandoz appoints new Board representative to global AMR Industry Alliance (GlobeNewswire)
20.05.22	Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions (GlobeNewswire)
12.05.22	Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer (GlobeNewswire)
04.05.22	New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients (GlobeNewswire)
27.04.22	Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study (GlobeNewswire)
26.04.22	Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook (GlobeNewswire)
26.04.22	Novartis erzielt ein solides Umsatz- und Gewinnwachstum. Die starke Performance auf dem Markt befindlicher Marken stützt das Vertrauen in die mittelfristigen Wachstumsaussichten (GlobeNewswire)
22.04.22	Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer (GlobeNewswire)
14.04.22	Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio (GlobeNewswire)
06.04.22	Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR) (GlobeNewswire)
06.04.22	FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS) (GlobeNewswire)
05.04.22	Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility (GlobeNewswire)
04.04.22	Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity (GlobeNewswire)
04.04.22	Novartis gibt neue Organisationsstruktur bekannt für schnelleres Wachstum, eine stärkere Pipeline und höhrere Produktivität (GlobeNewswire)
25.03.22	Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease (GlobeNewswire)
25.03.22	Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe (GlobeNewswire)
23.03.22	Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer (GlobeNewswire)
14.03.22	Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce (GlobeNewswire)
14.03.22	Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection (GlobeNewswire)
04.03.22	Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting (GlobeNewswire)
04.03.22	Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut (GlobeNewswire)
18.02.22	Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine (GlobeNewswire)
02.02.22	Novartis erzielt 2021 ein Umsatzwachstum im mittleren einstelligen Bereich, verbessert die Margen und treibt die solide Pipeline voran (GlobeNewswire)
02.02.22	Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021 (GlobeNewswire)
10.01.22	Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 (GlobeNewswire)
04.01.22	Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent (GlobeNewswire)
23.12.21	Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis (GlobeNewswire)
22.12.21	FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year (GlobeNewswire)
22.12.21	Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness (GlobeNewswire)
22.12.21	Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA (GlobeNewswire)
20.12.21	Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA (GlobeNewswire)
20.12.21	Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab (GlobeNewswire)
20.12.21	Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU) (GlobeNewswire)
16.12.21	Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline (GlobeNewswire)
16.12.21	Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline (GlobeNewswire)
13.12.21	Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021 (GlobeNewswire)
11.12.21	Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia (GlobeNewswire)
11.12.21	Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up (GlobeNewswire)
10.12.21	Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i (GlobeNewswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’833.00	0.87 %	K V
Nestle	90.24	0.78 %	K V
Roche Hldg G	296.70	0.78 %	K V
Sonova Hldg	262.80	0.42 %	K V
Kuehne+Nagel Int	206.70	0.39 %	K V
Part Grp Hldg	1’291.50	-1.45 %	K V
Logitech Intl	77.34	-1.65 %	K V
Geberit	558.20	-1.86 %	K V
ABB	46.96	-2.69 %	K V
Swisscom	513.00	-3.93 %	K V

mehr

28.03.25		Angespannte Stimmung in New York: Dow Jones fällt letztendlich
28.03.25		Freitagshandel in New York: S&P 500 gibt nachmittags nach
28.03.25		Angespannte Stimmung in New York: Dow Jones gibt nachmittags nach
28.03.25		Novartis-Aktie: FDA erteilt erweiterte Zulassung für Krebsmedikament
28.03.25		Zurückhaltung in New York: Dow Jones präsentiert sich am Mittag schwächer